| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $2,019,476 ) |
| | 2024 | 2024 | INSTITUTE FOR MOLECULAR MEDICINE INC | 16371 GOTHARD ST | HUNTINGTON BEACH, CA | CA | 92647-3652 | | USA | R01AG074983 | Safety/Tolerability/Immunogenicity of first-in-human A? DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA. | 000 | 3 | NIH | 3/11/2024 | $2,019,476 |
| | 2024 | 2023 | INSTITUTE FOR MOLECULAR MEDICINE INC | 16371 GOTHARD ST | HUNTINGTON BEACH, CA | CA | 92647-3652 | | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 002 | 4 | NIH | 12/7/2023 | $0 |
| | 2024 | 2022 | INSTITUTE FOR MOLECULAR MEDICINE INC | 16371 GOTHARD ST | HUNTINGTON BEACH, CA | CA | 92647-3652 | | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 001 | 4 | NIH | 12/7/2023 | $0 |
| | 2024 | 2022 | INSTITUTE FOR MOLECULAR MEDICINE INC | 16371 GOTHARD ST | HUNTINGTON BEACH, CA | CA | 92647-3652 | | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 000 | 4 | NIH | 12/7/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $5,377,617 ) |
| | 2023 | 2023 | INSTITUTE FOR MOLECULAR MEDICINE INC | 16371 GOTHARD ST | HUNTINGTON BEACH, CA | CA | 92647-3652 | | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 000 | 4 | NIH | 12/20/2022 | $2,270,000 |
| | 2023 | 2023 | INSTITUTE FOR MOLECULAR MEDICINE INC | 16371 GOTHARD ST | HUNTINGTON BEACH, CA | CA | 92647-3652 | | USA | R01AG074983 | Safety/Tolerability/Immunogenicity of first-in-human A? DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA. | 004 | 2 | NIH | 4/19/2023 | $699,000 |
| | 2023 | 2023 | INSTITUTE FOR MOLECULAR MEDICINE INC | 16371 GOTHARD ST | HUNTINGTON BEACH, CA | CA | 92647-3652 | | USA | R01AG074983 | Safety/Tolerability/Immunogenicity of first-in-human A? DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA. | 003 | 2 | NIH | 4/10/2023 | $2,408,617 |
| | 2023 | 2022 | INSTITUTE FOR MOLECULAR MEDICINE INC | 16371 GOTHARD ST | HUNTINGTON BEACH, CA | CA | 92647-3652 | | USA | R01AG074983 | Safety/Tolerability/Immunogenicity of first-in-human A? DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA. | 002 | 1 | NIH | 2/13/2023 | $13,381 |
| | 2023 | 2022 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | R01AG074983 | Safety/Tolerability/Immunogenicity of first-in-human A? DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA. | 000 | 1 | NIH | 10/18/2022 | $0 |
| | 2023 | 2022 | INSTITUTE FOR MOLECULAR MEDICINE INC | 16371 GOTHARD ST | HUNTINGTON BEACH, CA | CA | 92647-3652 | | USA | R01AG074983 | Safety/Tolerability/Immunogenicity of first-in-human A? DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA. | 001 | 1 | NIH | 2/8/2023 | -$13,381 |
| | 2023 | 2018 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | RF1AG020241 | Multiple Approaches to Abeta Vaccination in Animal Models | 000 | 16 | NIH | 10/28/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $5,216,400 ) |
| | 2022 | 2022 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 001 | 4 | NIH | 3/1/2022 | $297,719 |
| | 2022 | 2022 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 000 | 4 | NIH | 2/28/2022 | $2,014,174 |
| | 2022 | 2022 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | R01AG074983 | Safety/Tolerability/Immunogenicity of first-in-human A? DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA. | 000 | 1 | NIH | 2/14/2022 | $2,680,709 |
| | 2022 | 2022 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 002 | 4 | NIH | 5/5/2022 | $223,798 |
|
| Issue Date FY: 2021 ( Subtotal = $3,438,418 ) |
| | 2021 | 2021 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 000 | 3 | NIH | 3/4/2021 | $357,084 |
| | 2021 | 2021 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 001 | 3 | NIH | 4/23/2021 | $1,346,072 |
| | 2021 | 2021 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 000 | 3 | NIH | 3/4/2021 | $1,315,772 |
| | 2021 | 2021 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 002 | 3 | NIH | 9/8/2021 | $419,490 |
| | 2021 | 2018 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | R01NS050895 | Combining AD Epitope Vaccine with Innate Immunity | 000 | 15 | NIH | 1/21/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,661,397 ) |
| | 2020 | 2020 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 000 | 2 | NIH | 3/14/2020 | $1,272,333 |
| | 2020 | 2020 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 001 | 2 | NIH | 8/11/2020 | $389,064 |
| | 2020 | 2020 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 002 | 2 | NIH | 8/14/2020 | -$389,064 |
| | 2020 | 2020 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 002 | 2 | NIH | 8/14/2020 | $389,064 |
| | 2020 | 2018 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | R21NS101504 | The Dimer Specific Anti-Amyloid-? Vaccine Based on the Nanoarray Assembly | 000 | 2 | NIH | 3/24/2020 | $0 |
| | 2020 | 2018 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | RF1AG020241 | Multiple Approaches to Abeta Vaccination in Animal Models | 000 | 16 | NIH | 12/13/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,116,260 ) |
| | 2019 | 2019 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG060965 | Manufacturing of Drug Product, Dual A?/tau Vaccine for Clinical Trials | 000 | 1 | NIH | 1/29/2019 | $1,116,260 |
| | 2019 | 2018 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG048310 | Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND | 000 | 4 | NIH | 7/24/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $5,182,632 ) |
| | 2018 | 2018 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | R01NS050895 | Combining AD Epitope Vaccine with Innate Immunity | 000 | 15 | NIH | 6/22/2018 | $616,130 |
| | 2018 | 2018 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG048310 | Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND | 001 | 4 | NIH | 6/23/2018 | -$927,669 |
| | 2018 | 2018 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | R21NS101504 | The Dimer Specific Anti-Amyloid-? Vaccine Based on the Nanoarray Assembly | 000 | 2 | NIH | 3/19/2018 | $268,656 |
| | 2018 | 2018 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | R21NS101504 | The Dimer Specific Anti-Amyloid-? Vaccine Based on the Nanoarray Assembly | 001 | 2 | NIH | 4/25/2018 | $29,852 |
| | 2018 | 2018 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | RF1AG020241 | Multiple Approaches to Abeta Vaccination in Animal Models | 000 | 16 | NIH | 8/22/2018 | $694,163 |
| | 2018 | 2018 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG048310 | Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND | 000 | 4 | NIH | 4/20/2018 | $927,669 |
| | 2018 | 2018 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG048310 | Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND | 001 | 4 | NIH | 6/23/2018 | $927,669 |
| | 2018 | 2018 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | RF1AG020241 | Multiple Approaches to Abeta Vaccination in Animal Models | 001 | 16 | NIH | 9/21/2018 | $2,646,162 |
|
| Issue Date FY: 2017 ( Subtotal = $2,060,622 ) |
| | 2017 | 2017 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG048310 | Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND | 001 | 3 | NIH | 6/22/2017 | $125,381 |
| | 2017 | 2017 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | R01NS050895 | Combining AD Epitope Vaccine with Innate Immunity | 000 | 13 | NIH | 4/3/2017 | $10,210 |
| | 2017 | 2017 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | R01NS050895 | Combining AD Epitope Vaccine with Innate Immunity | 001 | 14 | NIH | 6/16/2017 | $615,802 |
| | 2017 | 2017 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | U01AG048310 | Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND | 000 | 3 | NIH | 5/1/2017 | $1,128,434 |
| | 2017 | 2017 | INSTITUTE FOR MLCULAR MEDICINE | 16371 GOTHARD ST. H | HUNTINGTON BEACH | CA | 92647-3652 | ORANGE | USA | R21NS101504 | The Dimer Specific Anti-Amyloid-? Vaccine Based on the Nanoarray Assembly | 000 | 1 | NIH | 2/13/2017 | $180,795 |
|
| Issue Date FY: 2016 ( Subtotal = $1,791,772 ) (Continued on the next page) |
|
